Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G. Schwartz, Andreas M. Zeiher, Jean‐François Tamby et al.|New England Journal of Medicine|2018Cited by 3.5k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialAdrian F. Hernandez, Lauren B. Cooper, Jennifer B. Green et al.|The Lancet|2018Cited by 1.8k
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38Stephen D. Wiviott, Elliott M. Antman, Eugene Braunwald et al.|Circulation|2008Cited by 757
Intravenous Platelet Blockade with Cangrelor during PCIDeepak L. Bhatt, Robert A. Harrington, A. Michael Lincoff et al.|New England Journal of Medicine|2009Cited by 643
Platelet Inhibition with Cangrelor in Patients Undergoing PCIRobert A. Harrington, Deepak L. Bhatt, Gregg W. Stone et al.|New England Journal of Medicine|2009Cited by 618